Rezolute Announces Positive Interim Phase 3 Results for Ersodetug in Tumor Hyperinsulinism
Rezolute (RZLT) has reported encouraging interim data from its Phase 3 upLIFT clinical study evaluating ersodetug for the treatment of tumor hyperinsulinism. The preliminary results indicate significant efficacy, with 13 out of 16 enrolled patients achieving at least a 50% reduction from baseline in their glucose infusion rate (GIR). The GIR reduction is a critical clinical metric used to measure the severity of hypoglycemia in these patients. These findings suggest that ersodetug may provide a meaningful therapeutic option for managing this condition, potentially impacting the market landscape for metabolic disorder treatments.
Tickers: $RZLT
Topics: ersodetug glucose infusion rate Phase 3 clinical trial tumor hyperinsulinism